Market Closed -
London S.E.
11:35:23 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
5
GBX
|
-4.76%
|
|
-.--%
|
-51.22%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1.017
|
1.119
|
1.119
|
4.933
|
10.59
|
Enterprise Value (EV)
1 |
0.4648
|
0.6736
|
0.7588
|
4.103
|
8.43
|
P/E ratio
|
-3.41
x
|
-11.9
x
|
-19.2
x
|
-2.79
x
|
-6.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
818,423,428
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
651,360,609
x
|
EV / EBITDA
|
-
|
-
|
-
|
-5,512,622
x
|
-5,658,113
x
|
EV / FCF
|
-
|
-9,369,761
x
|
-7,907,053
x
|
-9,320,146
x
|
-9,285,493
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
1.97
x
|
2.64
x
|
3.07
x
|
1.38
x
|
2.18
x
|
Nbr of stocks (in thousands)
|
20,340
|
20,340
|
20,340
|
85,783
|
103,337
|
Reference price
2 |
0.0500
|
0.0550
|
0.0550
|
0.0575
|
0.1025
|
Announcement Date
|
2/3/20
|
3/31/21
|
2/14/22
|
1/31/23
|
2/1/24
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
0.0129
|
EBITDA
|
-
|
-
|
-
|
-0.7443
|
-1.49
|
EBIT
1 |
-0.0252
|
-0.0938
|
-0.1106
|
-0.7517
|
-1.523
|
Operating Margin
|
-
|
-
|
-
|
-
|
-11,769.39%
|
Earnings before Tax (EBT)
1 |
-0.0871
|
-0.0938
|
-0.0583
|
-0.9294
|
-1.58
|
Net income
1 |
-0.0871
|
-0.0938
|
-0.0583
|
-0.93
|
-1.501
|
Net margin
|
-
|
-
|
-
|
-
|
-11,598.22%
|
EPS
2 |
-0.0147
|
-0.004613
|
-0.002867
|
-0.0206
|
-0.0159
|
Free Cash Flow
|
-
|
-0.0719
|
-0.096
|
-0.4402
|
-0.9079
|
FCF margin
|
-
|
-
|
-
|
-
|
-7,014.82%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/3/20
|
3/31/21
|
2/14/22
|
1/31/23
|
2/1/24
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.55
|
0.45
|
0.36
|
0.83
|
2.16
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-0.07
|
-0.1
|
-0.44
|
-0.91
|
ROE (net income / shareholders' equity)
|
-
|
-20%
|
-14.8%
|
-47.1%
|
-35.6%
|
ROA (Net income/ Total Assets)
|
-
|
-11.6%
|
-16.1%
|
-21.2%
|
-20.5%
|
Assets
1 |
-
|
0.8068
|
0.3616
|
4.389
|
7.326
|
Book Value Per Share
2 |
0.0300
|
0.0200
|
0.0200
|
0.0400
|
0.0500
|
Cash Flow per Share
2 |
0.0300
|
0.0200
|
0.0200
|
0.0100
|
0.0200
|
Capex
|
-
|
-
|
-
|
0.01
|
0.06
|
Capex / Sales
|
-
|
-
|
-
|
-
|
501.07%
|
Announcement Date
|
2/3/20
|
3/31/21
|
2/14/22
|
1/31/23
|
2/1/24
|
|
1st Jan change
|
Capi.
|
---|
| -51.22% | 6.47M | | -3.81% | 86.85B | | +2.76% | 40.16B | | -16.98% | 31.28B | | +57.86% | 25.27B | | -16.24% | 15.33B | | -9.12% | 11.96B | | -42.56% | 11.61B | | -17.10% | 11.69B | | +6.89% | 8.83B |
Biopharmaceuticals
|